ZLAB · Zai Lab Limited
$24.14
-0.12% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-11.5
Dividend yield
—
Beta
0.83
Avg volume
1M
Employees
2K
Daily Change %
-0.12%
5 Days Change
-4.38%
10 Days Change
-1.49%
30 Days Change
-3.54%
60 Days Change
22.40%
Month to Day Change
-0.87%
Year to Day Change
42.18%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ZLAB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-07
Latest call per bank · past 12 months
Citigroup
Buy$45.00
+86.2% vs priceJP Morgan
Overweight$32.00
+32.4% vs priceUBS
Buy$35.00
+44.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Citigroup | Maintains | Buy | $44.00 → $45.00 |
| 2026-05-08 | Citigroup | Maintains | Buy | $47.00 → $44.00 |
| 2026-03-18 | JP Morgan | Maintains | Overweight | $39.00 → $32.00 |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight | $55.00 → $37.00 |
| 2026-02-05 | JP Morgan | Maintains | Overweight | $46.00 → $39.00 |
| 2026-01-07 | UBS | Initiates | Buy | $0.00 → $35.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.2% above the 50-day MA ($22.53).
- Price vs 200-day MA: Trading 21.2% above the 200-day MA ($19.92).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.46) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.30) and high ($34.44).
ZLAB Price Chart
Loading chart for ZLAB…
Fundamentals
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.